jump to content jump to footer

Comparison of iRECIST and RECIST 1.1 for Evaluating Immunotherapy in Melanoma and Non-Small Cell Lung Cancer

In a retrospective study conducted at the University Hospital Cologne, the radiological criteria iRECIST and RECIST 1.1 were compared for assessing treatment response in melanoma and NSCLC patients receiving immune checkpoint inhibitors.

The results indicate that iRECIST is better suited for capturing atypical treatment responses to immunotherapies, especially in patients experiencing pseudoprogression. iRECIST could thus contribute to a more accurate evaluation of treatment response and improved immunotherapy outcomes.

Read more about the study here.

Research with mint mintLesion Clinical Research Standardized Reading Procedures iRECIST RECIST

Related Resources

Portrait of Professor Christina Messiou, Consultant Radiologist at The Royal Marsden NHS Foundation Trust
Professor Christina Messiou, Consultant Radiologist at The Royal Marsden NHS Foundation Trust and Professor at the Institute of Cancer Research, discusses AI-powered whole-body MRI for multiple myeloma
AI-Powered Whole-Body MRI for Multiple Myeloma: Interview with Prof. Christina Messiou
Multiple myeloma poses a unique challenge for radiologists: the disease often affects the bone marrow unevenly, and conventional biopsies can only…
Interview with PD Dr. med. Thi Dan Linh Nguyen-Kim: Structured Reporting in Clinical Practice
In this interview, PD Dr. med. Thi Dan Linh Nguyen-Kim, Head of Department and Institute Director of Radiology and Nuclear Medicine at Stadtspital…
Radiologist reviewing whole-body MRI images with AI-supported tumor burden quantification for bone metastases and multiple myeloma using mint Lesion.
Mint Medical has integrated an AI algorithm developed by The Institute of Cancer Research and The Royal Marsden into mint Lesion. The solution supports bone disease assessment and treatment response evaluation in advanced prostate cancer and multiple myeloma.
The ICR and The Royal Marsden work with Mint Medical to integrate AI-powered software into cancer treatment
The Institute of Cancer Research (ICR), London, and The Royal Marsden NHS Foundation Trust have announced a new licensing agreement with MedTech…